skip to Main Content

Closing the gate on SARS-CoV-2: A VSV pseudotype neutralization assay targeting the key to viral entry

To address the urgent and immediate need for R&D tools for the fight against the public health threat from SARS-CoV-2, IBT Bioservices now offers a pseudotype virus system to assay inhibition of infectivity in a BSL-2 environment. Briefly, Vesicular Stomatitis virus (VSV) glycoprotein gene (G) has been substituted with SARS-CoV-2 Spike Protein (rVSV pseudotyped SARS-CoV-2 Spike). The recombinant rVSV-DG SARS-CoV-2 Spike has been incorporated into a convenient luciferase-based neutralization assay for evaluating the efficacy of drug candidates that target Spike-mediated infection (Figure 1). This system is similar to previously published and validated VSV pseudotype platform for Ebolavirus and Marburgvirus1,2,3.

Key advantages: The heavily glycosylated Spike proteins on its surface give Coronavirus a crown-like appearance. These Spike proteins recognize the ACE2 receptor on the host cell surface to facilitate viral entry and fusion (inset). Anti-Spike antibodies have been detected in convalescent patient plasma suggesting the S is immunogenic. It is a key determinant of host and cell tropism, antigenicity and immunogenicity, interspecies transmission as well as pathogenesis4 therefore an attractive candidate for antiviral inhibitors and vaccine development5,6,7.

Read More
Back To Top
×Close search
Search

IBT Bioservices continues to conduct critical work as an essential business under the State of Maryland’s COVID-19 response directive. We have implemented a risk management plan and are continually monitoring the situation to ensure continuation of research according to public health services recommended best-practices for keeping our employees and the community safe. 

The IBT Bioservices team will continue to deliver high quality products and services for every project. If you have any questions contact us at Services@IBTBioservices.com